<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03562754</url>
  </required_header>
  <id_info>
    <org_study_id>2016/NIMAO2/OM-01</org_study_id>
    <nct_id>NCT03562754</nct_id>
  </id_info>
  <brief_title>Controlled Trial of Intermittent Hemodialysis With Regional Citrate VS Systemic Low Dose Heparin in Patients at Risk of Bleeding</brief_title>
  <acronym>ROBIN</acronym>
  <official_title>Randomized Controlled Trial of Intermittent Hemodialysis With Regional Citrate Anticoagulation Versus Systemic Low Dose Heparin Anticoagulation in Patients at Risk of Bleeding in Nephrology Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigators hypothesize that intermittent hemodialysis with regional citrate
      anticoagulation (Prometheus system/Frésénius) is more efficient than reduced systemic heparin
      anticoagulation in patients at bleeding risk hospitalized in nephrology intensive care unit
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2019</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of intermittent hemodialysis between groups</measure>
    <time_frame>End of intermittent hemodialysis session (average 4 hours)</time_frame>
    <description>Minutes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemodialysis treatment adequacy</measure>
    <time_frame>End of intermittent hemodialysis session (average 4 hours)</time_frame>
    <description>KT/V value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transmembrane pressure between groups</measure>
    <time_frame>End of intermittent hemodialysis session (average 4 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood aspect in the extracorporeal treatment circuit</measure>
    <time_frame>End of intermittent hemodialysis session (average 4 hours)</time_frame>
    <description>Clotting phenomena</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of hemorrhage</measure>
    <time_frame>Hour 12</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of metabolic disorders (hypocalcemia, metabolic alkalose)</measure>
    <time_frame>Hour 12</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurance of unexpected complications (almost none recorded in the literature)</measure>
    <time_frame>End of intermittent hemodialysis session (average 4 hours)</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hemodialysis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prometheus System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>reduced systemic heparin anticoagulation</intervention_name>
    <description>receive intermittent hemodialysis (Frésenius 4008) with blood flow at least of (200 ml/min) with double vascular access, biocompatible membrane dialyzer, low dose non fractionated heparine (5000 UI initially) and predilution with 25 mls/min dialysate</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Regional Citrate Anticoagulation</intervention_name>
    <description>intermittent hemodialysis using Prometheus System with blood flow at least of 200 ml/min with double vascular access, biocompatible membrane dialyzer</description>
    <arm_group_label>Prometheus System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has been correctly informed.

          -  The patient must have given his/her informed and signed consent.

          -  The legal guardian or trusted-person of an adult under guardianship must have given
             their informed and signed consent.

          -  The patient has health insurance coverage via the French social security system.

          -  The patient is at least 18 years old.

          -  The patient is at bleeding risk; the bleeding risk is defined by the clinical
             situation and according to predefined clinical situations (before or after surgery or
             biopsy, hemorrhage).

          -  The patient requires an intermittent hemodialysis in a nephrology ICU setting.

        Exclusion Criteria:

          -  The patient is participating in, or has participated in over the past three months,
             another interventional trial.

          -  The patient is in an exclusion period determined by a previous study.

          -  The patient is under judicial protection.

          -  The parents (or legal guardian) of the patient refuse to sign the consent.

          -  It is impossible to correctly inform the patient/parents (or legal guardian) of the
             patient (language barrier).

          -  Contraindication to heparin treatment.

          -  Indication of continuous dialysis in ICU.

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Moranne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier Moranne, MD</last_name>
    <phone>04.66.68.32.57</phone>
    <email>olivier.moranne@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>+33 (0)4.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier Moranne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal Reboul, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvain Cariou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Renaud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédérique Vecina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 8, 2018</study_first_submitted>
  <study_first_submitted_qc>June 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

